Ken Griffin Provention Bio, Inc. Call Options Transaction History

Citadel Advisors LLC

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 15, 2023	SELL	$6.7 - $24.21 $968,150 - $3.5 Million	-144,500 Reduced 38.94%	226,600 $5.46 Million
Q4 2022 Feb 14, 2023	BUY	$4.52 - $10.57 $899,479 - $2.1 Million	199,000 Added 115.63%	371,100 $3.92 Million
Q3 2022 Nov 14, 2022	BUY	$3.43 - $5.62 $25,382 - $41,588	7,400 Added 4.49%	172,100 $774,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.